Achieve Life Sciences Inc
$ 3.49
5.12%
10 Apr - close price
- Market Cap 176,757,000 USD
- Current Price $ 3.49
- High / Low $ 3.49 / 3.30
- Stock P/E N/A
- Book Value 0.40
- EPS -1.25
- Next Earning Report 2026-05-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.85 %
- ROE -2.58 %
- 52 Week High 6.03
- 52 Week Low 1.95
About
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and markets cytisinicline for smoking and nicotine addiction cessation in the United States and internationally. The company is headquartered in Vancouver, Canada.
Analyst Target Price
$14.75
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-12 | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-03-26 | 2024-11-07 | 2024-08-13 | 2024-05-09 | 2024-03-13 | 2023-11-09 | 2023-08-14 | 2023-05-09 |
| Reported EPS | -0.28 | -0.28 | -0.37 | -0.37 | -0.36 | -0.36 | -0.25 | -0.26 | -0.26 | -0.34 | -0.43 | -0.5 |
| Estimated EPS | -0.2771 | -0.24 | -0.37 | -0.3657 | -0.36 | -0.26 | -0.23 | -0.24 | -0.31 | -0.38 | -0.42 | -0.69 |
| Surprise | -0.0029 | -0.04 | 0 | -0.0043 | 0 | -0.1 | -0.02 | -0.02 | 0.05 | 0.04 | -0.01 | 0.19 |
| Surprise Percentage | -1.0466% | -16.6667% | 0% | -1.1758% | 0% | -38.4615% | -8.6957% | -8.3333% | 16.129% | 10.5263% | -2.381% | 27.5362% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-12 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.3 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ACHV
2026-04-10 15:10:30
Achieve Life Sciences, Inc. is actively engaged in developing new treatments for nicotine dependence. The company is committed to offering innovative solutions to help individuals overcome nicotine addiction. Their ongoing research aims to improve outcomes for those seeking to quit nicotine.
2026-03-30 08:10:14
Achieve Life Sciences (NASDAQ:ACHV) has received an average "Moderate Buy" rating from five brokerages, with an average 12-month target price of $15.50, significantly higher than its current trading price of $2.65. Key catalysts include a PDUFA date on June 20, 2026, and a planned Phase 3 vaping cessation trial, potentially leading to a commercial launch in the first half of 2027 if approved. Institutional ownership is around 33.5%, and recent call-option activity suggests speculative bullish positioning.
2026-03-27 12:40:18
Zacks Research has revised its FY2026 EPS estimate for Achieve Life Sciences (NASDAQ:ACHV) down to ($1.40) from ($1.07), with a consensus full-year estimate of ($1.17). The biopharmaceutical company recently reported a Q4 2025 EPS of ($0.28), missing analyst expectations, but upcoming catalysts such as the PDUFA date for cytisinicline and a planned Phase 3 vaping-cessation trial could significantly impact its valuation. Despite mixed analyst sentiment, the stock holds a "Moderate Buy" rating with substantial potential upside from its current trading price of $2.89 against an average target of $15.50.
2026-03-27 05:09:09
Achieve Life Sciences (NASDAQ: ACHV) announced the publication of research on its drug cytisinicline, highlighting its strong binding to the α4β2 nicotinic receptor and minimal interaction with the 5-HT3 receptor, which may explain the low incidence of nausea in clinical trials. The company's New Drug Application for cytisinicline as a smoking cessation treatment is under FDA review with a PDUFA date of June 20, 2026, though the commercial launch is now planned for the first half of 2027. Despite recent stock declines, analysts remain optimistic, citing the upcoming regulatory decision and setting price targets between $10 and $20.
2026-03-27 05:09:09
Achieve Life Sciences has published a new study in Nicotine & Tobacco Research on cytisinicline's receptor selectivity, explaining its low nausea rates in smoking and vaping cessation trials. The findings confirm that cytisinicline strongly binds to the α4β2 nicotinic receptor, essential for reducing nicotine cravings, while minimally interacting with the 5-HT3 serotonin receptor linked to nausea. This research provides a biological basis for the drug's favorable tolerability, supporting its potential as a new treatment for nicotine dependence.
2026-03-26 12:39:26
Achieve Life Sciences announced the publication of a study in Nicotine & Tobacco Research detailing cytisinicline's receptor selectivity. The research indicates that cytisinicline's strong binding to the α4β2 nicotinic receptor and minimal interaction with the 5-HT3 serotonin receptor likely contribute to its low nausea rates observed in clinical trials for smoking and vaping cessation. These findings support its favorable tolerability profile, which could be crucial for individuals attempting to quit nicotine dependence, a condition for which there are currently limited effective treatments.
